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Abstract
Background & Aims: Primary sclerosing cholangitis (PSC) is characterized by chronic 
cholestasis and inflammation, which promotes cirrhosis and an increased risk of chol-
angiocellular carcinoma (CCA). The transcription factor Krueppel-like-factor-6 (KLF6) 
is a mediator of liver regeneration, steatosis, and hepatocellular carcinoma (HCC), but 
no data are yet available on its potential role in cholestasis. Here, we aimed to iden-
tify the impact of hepatic KLF6 expression on cholestatic liver injury and PSC and 
identify potential effects on farnesoid-X-receptor (FXR) signalling.
Methods: Hepatocellular KLF6 expression was quantified by immunohistochemistry 
(IHC) in liver biopsies of PSC patients and correlated with serum parameters and 
clinical outcome. Liver injury was analysed in hepatocyte-specific Klf6-knockout mice 
following bile duct ligation (BDL). Chromatin-immunoprecipitation-assays (ChIP) and 
KLF6-overexpressing HepG2 cells were used to analyse the interaction of KLF6 and 
FXR target genes such as NR0B2.
Results: Based on IHC, PSC patients could be subdivided into two groups showing 
either low (<80%) or high (>80%) hepatocellular KLF6 expression. In patients with 
high KLF6 expression, we observed a superior survival in Kaplan-Meier analysis. Klf6-
knockout mice showed reduced hepatic necrosis following BDL when compared to 
controls. KLF6 suppressed NR0B2 expression in HepG2 cells mediated through bind-
ing of KLF6 to the NR0B2 promoter region.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  | INTRODUC TION
The ubiquitously expressed transcription factor Krüppel-like-
factor-6 (KLF6) has been established as a tumour suppressor gene 
and regulator of cell growth, differentiation, tumorigenesis, and 
signal transduction in numerous studies.1 Members of the KLF 
family are zinc-finger-proteins and have a conserved zinc finger 
DNA-binding domain, which is able to bind to GC-rich motifs on di-
verse target genes.2 KLF6 can act both as activator and repressor of 
transcription.3,4 Several studies indicated a general role for KLF6 in 
suppressing tumorigenesis by controlling key mechanisms involved 
in tumour formation, such as cell growth, differentiation, adhesion 
and endothelial motility.5-9 KLF6 expression or its functional loss 
have been associated with the progression and outcome of various 
tumours in patients, including hepatocellular carcinoma (HCC).10-12
Beside playing a role in HCC, KLF6 has been established as an 
important transcription factor in a variety of liver diseases, includ-
ing hepatic fibrogenesis, acute liver injury, ischaemia reperfusion 
damage and non-alcoholic fatty liver diseases (NAFLD).13-15 In the 
previous studies, we characterized KLF6 as a regulator of autophagy 
in acute liver injury and as a mediator of hepatic glucose and lipid 
metabolism in NAFLD by binding directly to the promoter regions of 
autophagy-regulating factors and hepatic glucokinase, as well as a 
post-transcriptional regulation of peroxisome proliferator activated 
receptor alpha (PPARα) expression.16-18 Interestingly, no data are yet 
available on a potential role of KLF6 in cholestatic liver diseases.
Primary sclerosing cholangitis (PSC) is a cholestatic liver disease 
characterized by chronic inflammation and consecutive constriction of 
the intra- and extra hepatic bile ducts resulting in progressive biliary fi-
brosis and cirrhosis.19 The underlying mechanisms are still insufficiently 
understood. The prevalence of PSC is notably increased in patients 
with chronic inflammatory bowel diseases, especially ulcerative colitis, 
predominantly in males.20 Chronic cholestasis such as in PSC drives 
hepatocellular injury followed by inflammation promoting cell prolif-
eration and tumorigenesis. Consecutively, PSC is associated with an 
increased risk of cholangiocellular carcinoma (CCA) and HCC.21 To re-
duce cholestasis in patients with so-called dominant strictures, dilata-
tion therapy via endoscopic retrograde cholangiopancreatography may 
be performed as a therapeutic option. While there is no established 
Medicine 6, Nürnberg, Germany
11Department of Immunology, 
Opthalmology and ORL, Complutense 
University School of Medicine, Madrid, 
Spain
12de Octubre Health Research Institute 
(imas 12), Madrid, Spain
Correspondence
Lars P. Bechmann, MD, MBA Ruhr-
University Bochum University Hospital 
Knappschaftskrankenhaus Department of 




EASL Andrew K. Burroughs short-term-
fellowship for SS, DFG for LPB (grant 
number BE3967/3-1), the Wilhelm-Laupitz-
Foundation for AC, the MINECO Retos 
SAF2016-78711, EXOHEP-CM S2017/
BMD-3727, NanoLiver-CM Y2018/
NMT-4949, ERAB Ref. EA 18/14, AMMF 
2018/117, UCM-25-2019 and COST Action 
CA17112 to FJC. FJC is a Ramón y Cajal 
Researcher RYC-2014-15242 and a Gilead 
Liver Research Scholar.
Handling Editor: Ana Lleo
Conclusion: Here, we show an association between KLF6 expression and the clinical 
course and overall survival in PSC patients. Mechanistically, we identified a direct 
interaction of KLF6 with the FXR target gene NR0B2.
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Key points
Chronic cholestasis can promote the development of 
chronic biliary inflammation, scarring of the liver and even 
hepatic cancer. So-called tumour suppressor genes, such 
as KLF6, have been identified to play crucial roles in the 
response to liver injury, far beyond their contribution to 
tumour formation. In this study, we investigate the effects 
of KLF6 expression on cholestasis and the development of 
billiary inflammation in patients with chronic cholestasis as 
well as in an animal model. We further aimed to identify 
the underlying mechanisms in a cell culture model. Our 
data indicate a novel mechanistic interaction of KLF6 with 
target genes of the FXR regulated bile acid metabolism.
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medical therapy, antibiotics are considered for treatment of bacterial 
cholangitis. As high-dose therapy appears harmful, some patients might 
benefit from low-dose ursodeoxycholic acid (UDCA) and early stage 
clinical studies suggest a beneficial effect of Farnesoid X Receptor 
(FXR) agonists in PSC.22 With established cirrhosis, liver transplanta-
tion is the only therapeutic option in progressive disease.23-25
Nuclear receptors, such as FXR, are ligand-activated transcrip-
tion factors controlling crucial biological functions including cell 
growth, glucose and lipid metabolism, as well as bile acid synthesis 
and systemic bile acid accumulation and therefore represent promis-
ing therapeutic targets for various diseases.26 Several FXR agonists 
are currently being tested in clinical trials as treatment options for 
cholestatic liver diseases. Among them, obeticholic acid (OCA) is al-
ready an established treatment option for primary biliary cholangitis 
(PBC), another autoimmune cholestatic liver disease.27-29 While we 
have established KLF6 as a regulator of the nuclear receptor PPARα, 
others found KLF6 to repress the nuclear receptor PPARγ and in-
teract with its cofactor Retinoid-X-Receptor alpha (RXRα).18,30,31 
However, no data are available yet on a potential interaction be-
tween KLF6 and the nuclear receptor FXR.
As FXR signalling is established as an important factor in cholesta-
sis, we aimed to investigate the interaction of KLF6, FXR and its target 
genes in cholestatic liver diseases and potential effects of KLF6 ex-
pression on clinical features of PSC in a well-defined cohort.
2  | METHODS
2.1 | Patient material and ethical considerations
For this study we analysed retrospective data and stored sam-
ple biopsies from PSC and PBC patients that were treated in the 
Department of Gastroenterology and Hepatology at the University 
Hospital Essen. All PSC and PBC patients, biopsied in our institution 
between January 2008 and December 2016 with sufficient paraffin 
tissue as well as historical laboratory and clinical data from the time 
of biopsy available were included. For Kaplan-Meier analysis, the 
clinical course of patients was followed until May 2019.
All investigations in human material and the use of patients’ data 
were approved by the Ethics Committee (Institutional Review Board) 
of the University Hospital Essen (reference number: 14-6065-BO) 
and the study protocol conformed to the ethical guidelines of the 
Declaration of Helsinki. As patient data and samples of the historic 
cohort of PSC and PBC patients were analysed retrospectively from 
stored samples that were obtained for routine clinical use, informed 
consent from these subjects was explicitly not required according to 
the local ethics committee.
2.2 | Statistical analysis
Statistical significance was determined using an unpaired (or paired, 
when applicable), two-tailed t test or by one-way ANOVA (with 
Tukey's post-hoc test for individual experimental conditions) as well 
as Kaplan-Meier survival analysis were performed with GraphPad 
Prism 8 (GraphPad Software Inc). Significance was assumed at 
P ≤ .05. If not stated otherwise all data are presented as mean ± SEM.
All additional information on the individual experimental meth-
ods and materials are described in the Data S1 section.
3  | RESULTS
3.1 | Hepatocyte KLF6 expression is associated with 
clinical outcome in PSC
KLF6 expression levels were quantified in liver tissue obtained 
for different clinical indications in patients with established diag-
nosis of large duct PSC, as assessed via MRCP and later treated 
with dilation therapy via ERCP. We included a total number of 19, 
predominantly male PSC patients with large duct disease with 
a mean age of 42.7 ± 10.6 years. Further demographic data and 
clinical features can be found in Table 1. Based on hepatocyte 
expression levels of KLF6 in patients’ liver biopsies, as assessed 
by immunohistochemistry, we identified two clusters of either 
high (>80%) or low (<80%) KLF6 expression in hepatocytes. This 
pattern was even more pronounced when exluding patients, 
TA B L E  1   Comparison of demographic, clinical, histological 
and laboratory data of PSC patients with KLF6 low (n = 9) and 
KLF6 high (n = 10) hepatocyte expression levels; a comparison 
of the groups showed no significant differences for the different 





Gender 8 m/1 f 7 m/3 f
Age (years) 41.4 ± 2.6 43.9 ± 5.0
Therapeutic ERCP 9/9 8/10
Intrahepatic Manifestation 9/9 8/10
Extrahepatic Manifestation 3/9 2/10
ANCA (pos/T) 1/9 4/10
AIH overlap (pos/T) 3/9 2/10
UC (pos/T) 5/9 4/10
CCA (pos/T) 3/9 0/10
LTX (pos/T) 2/9 2/10
Deceased (pos/T) 4/9 1/10
ALT (U/L) 109.8 ± 31.6 80.0 ± 29.8
AST (U/L) 75.0 ± 34.3 92.4 ± 17.4
γGT (U/L) 311.4 ± 98.7 193.6 ± 117.9
AP (U/L) 390.6 ± 148.6 271.8 ± 118.8
Bilirubin (mg/dl) 2.4 ± 1.9 2.9 ± 0.4
Mayo PSC Risk Score 0.33 ± 0.5 -0.17 ± 0.5
Fibrosis> 3 (pos/T) 5/9 7/10
Ductular Proliferation (pos/T) 8/9 6/10
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who underwent liver transplantation (LTX), resulting in two 
clusters with either > 80% or < 60% of hepatocytes expressing 
KLF6 (Figure S1A,B). A significant number of KLF6 positive non-
parenchymal cells (ie cholangiocytes, Kupffer cells etc) was not 
observed (Figure 1A).
Based on these results and in order to investigate a potential 
influence of hepatocyte KLF6 expression on clinical features of 
PSC, we then arbitrarily separated these patients in two groups 
with either high expression (>80%, n = 10) or low expression (<80%, 
n = 9) of KLF6 in hepatocytes for further analysis. There were no 
significant differences of pANCA levels, the histological presence 
of fibrosis or ductular proliferation comparing the groups (Table 1). 
Patients with high KLF6 expression showed a trend towards lower 
serum levels of ALT (alanine aminotransferase), γGT (gamma glu-
tamytransferase) and AP (alkaline phosphatase), with higher AST 
(aspartate aminotransferase). However, these differences were not 
significant (Table 1). Interestingly, all three patients that developed 
CCA in the course of the disease as well as most who deceased 
during the observation period had low hepatocyte KLF6 expression 
(Figure 1B,C).
To compare the clinical outcome of the patients, we performed 
a Kaplan-Meier analysis to test the influence of KLF6 expression on 
patients’ survival. Here, given the small sample size, it was remark-
able that those patients who had higher hepatocyte KLF6 expression 
had significantly better survival rates than patients with low KLF6 
expression (Figure 1D). This effect was still present, while attenu-
ated, when we declared the time of surgery in the four individuals 
who underwent LTX as negative endpoint in the Kaplan-Meier anal-
ysis (Figure 1E).
In contrast, in our PBC cohort (see demographics in Table S2), 
the distribution of hepatocyte KLF6 expression was less accen-
tuated, based on a more even distribution between 1% and 92% 
(Figure S1C). When applying the 80% cutoff, in contrast to PSC, in 
PBC patients with high KLF6 expression we observed a trend to-
wards higher transaminase levels and a significantly elevated γGT, 
indicating potentially different roles of hepatic KLF6 in two distinct 
cholestatic diseases, PSC and PBC (Table S2). Our data indicate that 
higer hepatic KLF6 expression is associated with a better outcome 
in PSC.
3.2 | Attenuated liver injury with accentuated 
cholestasis in a model of hepatocyte specific Klf6-
knockout mice following bile duct ligation
To further analyse the impact of hepatocyte KLF6 on cholestatic 
liver injury, we utilized an established conditional knockout model 
with hepatocellular deletion of Klf6 (DeltaKlf6-hep) and performed 
BDL as a model of obstructive cholestasis and inflammation. Animals 
were sacrificed 2 weeks following BDL and we measured markers of 
liver injury in the serum. Although the results did not show significant 
changes, it seemed that BDL in DeltaKlf6-hep mice led to accentu-
ated cholestasis as indicated by higher levels of bilirubin and AP yet 
decreased serum levels of ALT, AST, and triglycerides as compared to 
F I G U R E  1   High hepatic KLF6 
expression levels are related to a 
better outcome in PSC. Shown are 
representative images of liver sections 
from PSC patients with low (n = 9) or high 
(n = 10) hepatocellular KLF6 expression 
(A); 40-fold magnification. Patients 
who developed CCA (B) or deceased 
(C) during the observation period had 
lower hepatic KLF6 expression as shown 
by quantification of KLF6 positive cells 
per total cells in four different visual 
fields. Survival of PSC patients shows 
a significantly better outcome in those 
patients with high KLF6 expression levels 
as shown by Kaplan-Meier survival curve 
excluding those patients who underwent 
liver transplantation (LTX) (D) or a 
compound of deceased and transplanted 
PSC patients (E); *P = .05
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WT animals (Figure 2). Additionally, liver tissue sections were evalu-
ated using a blinded scoring system to quantify steatosis, ballooning, 
lobular inflammation, portal inflammation, necrosis, ductular reac-
tion and fibrosis by an expert hepatopathologist. Following BDL, 
DeltaKlf6-hep animals showed slightly more cells with ballooning 
but significantly less necrotic cells were detected (Figure 2D). So in 
summary, a conditional Klf6 knockout affects the phenotype of the 
liver injury following BDL.
3.3 | Klf6 knockout affects expression of FXR target 
genes following BDL
The mRNA levels of Klf6 showed a robust (>20-fold) increase after 
BDL in WT mice, but not in DeltaKlf6-hep animals indicating that 
the sharp increase in Klf6 in BDL-treated WT mice is hepatocyte-
specific (Figure 3A). As FXR activation is involved in cholestasis and 
PSC, we next measured mRNA expression in the whole liver tissue 
of different FXR target genes and factors that are involved in bile 
acid transport and metabolism. In comparison to sham-operated 
mice, the expression of the FXR target gene Nr0b2 (encoding the 
small heterodimer partner SHP) increased following BDL with a 
slightly higher increase in DeltaKlf6-hep animals as compared to 
WT animals (Figure 3B). Additionally, protein levels of Nr0b2/Shp, 
as determined by Western blot analysis, were significantly increased 
in liver tissue of DeltaKlf6-hep animals in comparison to WT after 
BDL (Figure 3C/D). Bile acid de novo synthesis is regulated by SHP/
NR0B2 as it represses the transcription of Cyp7A1 (cytochrome p450 
family 7 subfamily A member 1), but here Cyp7A1 expression was in-
creased after BDL. However, Cyp7A1 expression did not differ be-
tween WT and DeltaKlf6-hep (Figure 4A). Expression levels of the 
bile acid exporters Abcb11, Slc51b and Abcc3 were slightly increased 
after BDL, whereas this effect was more prominent in DeltaKlf6-
hep (Figure 4B-D). Taken together, a conditional knockout of Klf6 in 
hepatocytes induces a modest attenuation of cholestatic liver injury 
and is characterized by induction of hepatic bile acid export and 
F I G U R E  2   Serum parameters 
of wildtype (WT) and conditional 
hepatocellular Klf6 knockout (DeltaKlf6-
hep) mice 2 weeks following bile duct 
ligation (BDL). Representative tissue 
sections (20-foldmagnification) from 
mouse liver of WT and DeltaKlf6-hep 
animals following BDL (A) as well as serum 
parameters of ALT, AST and alkaline 
phosphatase (B) as well as bilirubin 
and triglycerides (C). Histopathologic 
evaluation of liver injury following a 
blinded scoring system (describing 
steatosis, ballooning, lobular inflammation, 
portal inflammation, necrosis, ductular 
reaction and fibrosis) was determined in 
WT and DeltaKlf6-hep knockout animals 
2 weeks following sham or BDL (n = 5 
animals per group, data are shown as 
mean ± SEM) (D); *P = .05
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reduction of bile acid uptake mechanisms. Especially in the absence 
of Klf6 expression, expression levels of Nr0b2 were increased.
KLF6 is a transcriptional repressor of the FXR target gene NR0B2.
In different rat models, treatment with FXR agonists lowers serum 
levels of ALT and AST, decreases necrosis, inflammation, and bile 
duct proliferation following BDL.32,33 Our studies indicate that FXR 
signalling is over-activated in BDL-treated DeltaKlf6-hep knockout 
mice but not in sham-treated animals. Furthermore, the expression 
of Klf6 was increased in WT mice following BDL. The results suggest 
a close interaction of both factors, although interestingly in our PSC 
cohort we did not see significant differences of FXR expression in rela-
tion to KLF6 expression (Figure S1D). However, to examine the mutual 
F I G U R E  3   Expression levels of Klf6 and FXR target gene Nr0b2/Shp in liver tissue of wildtype (WT) and conditional hepatocellular Klf6 
knockout (DeltaKlf6-hep) mice 2 weeks after bile duct ligation (BDL). mRNA expression levels of Klf6 (A), and Nr0b2 (B) in liver tissue of WT 
and DeltaKlf6-hep knockout mice 2 weeks after sham or BDL (n = 5 animals per group) were measured via quantitative RT-PCR. Protein 
expression of Shp/Nr0b2 in whole mouse liver of WT and DeltaKlf6-hep animals was determined via western blot analysis (C), quantified via 
densitometric analysis and normalized to the housekeeping gene Hsp70 (D). Data are shown as mean ± SEM; *P = .05, **P = .01
F I G U R E  4   Expression levels of FXR 
target genes in liver tissue of wildtype 
(WT) and conditional hepatocellular Klf6 
knockout (DeltaKlf6-hep) mice 2 weeks 
after bile duct ligation (BDL). mRNA 
expression levels Cyp7A1 (A), Abcb11 (B), 
Slc51b (C) and Abcc3 (D) in liver tissue of 
WT and DeltaKlf6-hep knockout mice 
2 weeks after sham or BDL (n = 5 animals 
per group) were measured via quantitative 
RT-PCR. Data are shown as mean ± SEM; 
*P = .05
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interaction closer, we measured the expression of Klf6 in liver tissue of 
Fxr-/- knockout animals and observed an increase of Klf6 expression in 
Fxr-/- mice as compared to WT animals (Figure 5A).
To study the interaction of KLF6 and FXR signalling more closely 
we performed cell culture experiments using HepG2 and KLF6-
overexpressing HepG2 cells (HepG2-KLF6). KLF6 expression was 
induced by transient transfection with a KLF6 expression vector, 
which resulted in significant upregulation of KLF6 mRNA levels 
(Supplementary Figure S2A), which was also described previously.16 To 
analyse the transcriptional effects of KLF6 on FXR-controlled genes/
promoter elements we performed luciferase reporter assays with con-
trol and HepG2-KLF6 cells and different luciferase reporter vectors 
monitoring the promoter activation of the FXR target genes NR0B2, 
ABCB11, SLC51A and SLC51B. In addition, to stimulate FXR activa-
tion, we treated the cells with the bile acid CDCA. CDCA treatment 
did show significant activation of all the analysed FXR target genes as 
shown via reporter assay and on mRNA levels measured by qRT-PCR 
in HepG2 cells (Figure 5, Figure S2B-D). Treatment with CDCA did not 
influence mRNA levels of KLF6 while transfection with pcIneo-KLF6 
resulted in significant upregulation of KLF6 (Figure S2A).
KLF6 overexpression in HepG2-KLF6 cells significantly reduced 
NR0B2/SHP promoter activation. Even after CDCA treatment the 
activity of the NR0B2 promoter element could not be stimulated in 
HepG2-KLF6 cells (Figure 5B). The effect of reduced basal promoter 
activation was not seen for the other FXR target genes ABCB11, 
SLC51A or SLC51B in untreated HepG2-KLF6 cells. However, after 
treatment with CDCA, the activity of the ABCB11 promoter was 
significantly lower than in control HepG2 cells (Figure 5C-E). While 
CDCA treatment for 24 hours activates FXR target gene promoters, 
here KLF6 overexpression had no effect on the mRNA expression of 
FXR target genes (Figure S2). In summary, KLF6 represses the induc-
tion of NR0B2 and attenuates the activation of ABCB11 following 
CDCA stimulation.
3.4 | KLF6 binds directly to the promoter region of 
NR0B2 and represses its expression
Members of the KLF family bind with varying affinity to DNA-
binding sites of target gene promoters and therefore function as 
F I G U R E  5   KLF6 overexpression in 
HepG2 cells affects luciferase activity 
of FXR target genes and KLF6 binds to 
promoter region of NR0B2. Expression 
levels of Klf6 in liver tissue of female 
Fxr-/- knockout mice or wildtype controls 
(both n = 7 animals per group) was 
measured via quantitative RT-PCR (A) and 
did show a significant up-regulation in 
Fxr-/-. Luciferase activity was measured in 
HepG2 and KLF6 overexpressing HepG2 
cells (HepG2-KLF6) following transient 
transfection with specific reporter plasmid 
for NR0B2 (B), ABCB11 (C), SLC51α (D) 
and SLC51β (E) with and without CDCA 
stimulation (n = 3 individual cell culture 
experiments shown as mean ± SEM). 
The interaction of KLF6 with the 
NR0B2 promoter containing putative 
KLF6-binding motifs was confirmed by 
chromatin immunoprecipitation (ChIP) in 
HepG2 cells (n = 3 individual experiments) 
using a specific KLF6 antibody (F); IgG was 
used as a negative control, Histone-H3 
antibody was used as a positive control 
for ChIP; *P = .05, **P = .01, ***P = .001, 
****P> .0001
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transcriptional activators or repressors.34 Interestingly, FXR-binding 
elements (IR-1 sequences) in the promoter regions of FXR target 
genes overlap with potential binding sites for KLF6 (CACCC repre-
sents a prominent binding motif), which might explain inhibition of 
FXR-induced promoter activation in the presence of high levels of 
KLF6. We identified potential KLF6-binding motifs within the pro-
moter regions of NR0B2, and then confirmed transcriptional interac-
tion by luciferase reporter assays. To specify the direct interaction 
of KLF6 and the NR0B2 promoter region we performed ChIP assays 
in HepG2-KLF6 cells using a KLF6-specific antibody, which indeed 
showed that KLF6 binds directly to the promoter region of NR0B2 
(Figure 5F).
Our findings indicate that KLF6 influences FXR signalling by 
potentially binding to FXREs and therefore KLF6 may work as an 
agonist or antagonist. ChIP assay confirmed a physical interaction 
between KLF6 and the promoter region of the FXR target gene 
NR0B2. These experiments underline a potential role of KLF6 as a 
novel mediator in FXR signalling and give new options to examine 
the clinical context of cholestatic liver diseases.
4  | DISCUSSION
The clinical course of PSC is primarily characterized by cholestasis 
promoting fibrogenesis and the occurrence of cirrhosis. For ad-
vanced stage PSC, liver transplantation is the only curative option.
Here, we describe a novel interrelation between hepatic KLF6 
expression and overall-survival as well as a potential role in the 
formation of CCA in a small, but well-characterized cohort of PSC-
patients. Mechanistically, we propose a novel interaction of KLF6 
with FXR signalling via its functional target gene NR0B2 while the 
expression of FXR itself is unaffected by KLF6. In previous exper-
iments, we have shown that KLF6 contributes to different models 
of acute liver injury as an important regulator of autophagy.16 With 
experiments using the DeltaKlf6-hep animal model in cholestasis fol-
lowing BDL, we observed an effect of hepatocyte KLF6 on cholesta-
sis mediated cell-death while laboratory parameters of cholestasis 
appeared to be increased. In WT animals, as a response to choles-
tatic injury, the expression of Klf6 was strongly induced following 
BDL. Similarly, in PBC patients, hepatocyte KLF6 expression was 
associated with a more cholestatic laboratory profile.
The clinical data and experiments with DeltaKlf6-hep an-
imals point towards a mechanistic relation between Klf6 and 
cholestasis-associated factors. Further in vitro studies using KLF6-
overexpressing HepG2 cells point towards a direct interaction of 
KLF6 with the FXR target gene NR0B2 (SHP), an orphan receptor, 
which influences bile acid metabolism via repression of several tar-
get genes including Cyp7A1, the key mediator of hepatic bile acid 
synthesis. A previous study found that NR0B2 interacts with a SP2/
KLF6 complex during regulation of matrix metallopeptidase 9/
MMP9 expression via FXR.35 Here, FXR induced SHP displaces the 
complex of SP2 and KLF6 by binding to a SP1 motif. However, a di-
rect binding of SHP to KLF6 has not been described yet.
We identified a novel interaction of KLF6 with the regulation of 
bile acid metabolism. The composition of the bile acid pool consist-
ing of different primary and secondary bile acids and its regulation is 
dependent on different biological processes in different parts of the 
liver and the intestine. FXR is an important nuclear receptor regulat-
ing bile acid homeostasis and keeps the balance of circulating and de 
novo synthesis of bile acids. In the liver, FXR regulates the expres-
sion of multiple genes that are involved in cellular bile salt import and 
export as well as in bile salt synthesis.36 FXR interacts with RXRα via 
heterodimer formation to induce transcriptional activity. The het-
erodimer typically binds to a specific DNA sequence consisting of 
two inverted repeat sequences separated by one nucleotide (IR-1) 
within the promoter region of its target genes. FXR is mainly acti-
vated by steroids such as bile acids to regulate intracellular bile acid 
levels and synthesis by activation of FXR target genes. An important 
downstream target gene of FXR signalling represents NR0B2, which 
controls bile acid influx and synthesis by regulating the expression 
of the bile acid importer SLC10A11 encoding the Na+-taurocholate 
co-transporting polypeptide (NTCP). Modulation of FXR signalling 
influences metabolic homeostasis and genetic FXR variances are 
associated with insulin resistance and dyslipidaemia.35,37 In chronic 
cholestasis-related diseases such as PSC, FXR and its target genes 
have been described to reduce cholestasis-induced liver injury. 
Intestinal FXR expression influences transcription of bile acid trans-
porters and the expression of the fibroblast-growth-factor-19 in the 
intestines and via the close interaction of liver and gut within the 
enterohepatic circulation intestinal FXR regulation affects liver in-
jury.38 However, we did not observe alterations in FXR-IHC in liver 
tissue associated with KLF6 expression levels in PSC patients.
PSC is characterized by recurrent ascending cholangitis due to 
obstruction of the large intra- and extrahepatic bile ducts.39 PSC dif-
fers from PBC in that the hepatocellular damage is caused by ductu-
lar cholestasis of the interlobular bile ducts within the parenchyma.40 
Clinical data from patients with PBC, an autoimmune cholestatic 
disease with a unique pathophysiology, we observed a cholestatic 
pattern associated with hepatic KLF6 expression, comparable to our 
observations in the BDL model. In contrast, in PSC, KLF6 expression 
was associated with a trend toward a milder cholestasis and more 
strikingly, a better clinical outcome. Therefore, we propose a distinct 
effect of hepatocyte KLF6 in PSC, independent of cholestasis.
Besides acute-on-chronic organ failure, the insufficient bile 
flow or bile blockage causes necrosis, which promotes proliferation 
and thus the formation of hepatic tumours such as CCA and with a 
much lower incidence HCC. Tumorigenesis of CCA is complex and 
its timely detection and therapy is complicated due to limited detec-
tion rate, surgical and medical therapy options, tumour resistance 
and tumour-own survival strategies. Thus, CCA is associated with 
poor prognosis.41-43 Therapeutic agents such as FXR agonists show 
promising effects in cholestatic diseases in order to prevent bile acid 
overload causing liver injury and the use of FXR agonists has been 
proposed in the context of CCA treatment.44,45 It has been shown 
that the tumour suppressor gene KLF6 can inhibit the formation of 
numerous cancer types while the expression of the alternative splice 
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variant KLF6-SV1 is associated with enhanced tumour growth and a 
worse outcome in HCC.5-7,10,46 However, so far no data are available 
on potential effects of KLF6 on bile acid signalling, cholestatic injury 
or CCA tumorigenesis. While our cohort is clearly to small to draw 
conclusions on potential effects of KLF6 on CCA, we were able to 
show that all PSC patients developing CCA during the observation 
period had a low hepatocyte KLF6 expression. In tumorigenesis as 
well as PSC progression, different cell types have been proposed to 
play pivotal roles.47 While we mainly focused this work on hepato-
cyte KLF6 expression, we did not assess potential effects of KLF6 in 
non-parenchymal and progenitor cells in the context of cholestasis 
and CCA. However, these effects might explain in parts the contra-
dictory observations we made between PSC, PBC and the knockout 
model. This is a clear limitation of this study and has to be addressed 
in future projects.
Our data indicate that the hepatocellular expression of KLF6 is 
associated with the clinical course of PSC. Here, we show in a small, 
but well-defined cohort of PSC patients, that KLF6 expression is as-
sociated with the clinical outcome of PSC and may as well affect the 
development of CCA. We further mechanistically link KLF6 expres-
sion with FXR target genes that play pivotal roles in bile acid me-
tabolism. Using in vitro cell culture experiments we show that KLF6 
and the FXR target gene NR0B2 interact with each other via a direct 
binding of KLF6 to promoter regions of NR0B2. However, to confirm 
our results and especially validate a potential effect of KLF6 on tum-
origenesis in CCA, further studies need to be conducted.
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